Thursday, June 30, 2022
wellness India Expo
Home Tags Biocon

Tag: Biocon

CCI approves merger by absorption of Covidshield Technologies into Biocon Biologics

The target is a subsidiary of Biocon Limited, and it offers treatment for chronic and acute diseases such as diabetes, oncology, nephrology, cancer, and autoimmune diseases

Pharma industry reiterates its commitment to US$ 130 billon by 2030

Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance

Biocon Biologics & Serum Institute Life Sciences announce strategic alliance

BBL will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets. SILS to receive ~15% stake in BBL at a post-money valuation of ~$4.9 billion......................

Syngene clocks 12% growth in FY21 revenue at Rs. 2,184 crore

Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year......................

Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in...

This partnership, which marks the entry of Biocon’s generic formulations into Latin America, builds upon a successful association with Libbs, which began in 2017 to launch biosimilar Trastuzumab in Brazil....................

Advancements in digital technology critical to advancements in clinical trials

As per experts, the digital-enabled regulatory flexibility during the pandemic that had helped bring drugs faster to market needs to continue.....................

New ‘Global Biopharma Resilience Index’ lists 5 major challenges for the...

The global index compiled by global life sciences leader Cytiva, along with the Financial Times’ research arm Longitude has been built on the survey of 1,165 biopharma executives and healthcare policymakers across 20 countries..................

Biocon Biologics partners IDF to increase access to diabetes care

Becomes the first biosimilar insulin company to partner with International Diabetes Federation for enabling affordable access to insulins to people with diabetes worldwide.................

Biocon Biologics to offer its oncology biosimilars in over 30 countries

The company's agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars will enable access to Trastuzumab and Pegfilgrastim in Africa and Asia...................

Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules...

A calcineurin inhibitor, Tacrolimus has been particularly effective in treating patients of renal transplant for more than two decades..............